Correlation between expression of matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9) and angiogenesis in colorectal adenocarcinoma

Journal of Korean Medical Science

Volumn 14, Issue 3, 1999, Pages 263-270

  Kim, Tae Sook ^a   Kim, Young Bae ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

Adenocarcinoma; Angiogenesis factor; Colorectal neoplasms; Metalloproteinases

Indexed keywords

CD34 ANTIGEN; COLLAGENASE; GELATINASE; GELATINASE A; GELATINASE B; METALLOPROTEINASE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; BIOSYNTHESIS; COLORECTAL TUMOR; HUMAN; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; COLLAGENASES; COLORECTAL NEOPLASMS; GELATINASES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0033146396     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.1999.14.3.263     Document Type: Article

References (45)

1. Tryggvason K, Huhtala P, Reponen P, Munaut C, Pyke C, Danq K, Autio-Harmainen H. Expression of type IV collagenases in invasive tumor. Clin Exp Metastasis 1993; 10(Suppl): A79.
2. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121-5.
3. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-54.
4. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997; 182: 347-55.
5. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem 1990; 265: 11077-82.
6. Seltzer JL, Akers KT, Weingarten H, Grant GA, McCourt DW, Eisen AZ. Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides. J Biol Chem 1990; 265: 20409-13.
7. Tomita T, Iwata K. Matrix metalloproteinases and tissue inibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 1996; 9: 1255-64.
8. Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler-Stevenson WG. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991; 51: 439-44.
9. Jaziorka M, Haboubi NY, Shofield PF, Ogata Y, Nagase H, Woolley DE. Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma. Int J Colored Dis 1994; 9: 141-8.
10. Van der Steppen WJ, Hendriks T, Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer 1990; 45: 1071-8.
11. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996; 56: 190-6.
12. Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GWH. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNA in colorectal neoplasia. Am J Pathol 1992; 141: 389-96.
13. Pyke C, Ralfkiaer E, Tryggvason K, Danq K. mRNA for two type IV collagenases islocated in stromal cells in human colon cancer. Am J Pathol 1993; 142: 359-65.
14. Nielsen B, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Danq K. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996; 65: 57-62.
15. D'Errico A, Garbisa S, Liotta LA, Castronovo V, Stetler-Stevenson WG, Grigioni WF. Augmentaion of type IV collagenases, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol 1991; 4: 239-46.
16. Liotta LA. Type IV collagenase augmentation associated with colorectal and gastric cancer progression In: Genetic Mechanisms in Carcinogenesis and tumor Progression. New York: Wley-Liss, 1990: 203-12.
17. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
18. Saclarides TJ, Speziale NU, Drab E, Szeluga DJ, Rubin DB. Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 1994; 37: 921-6.
19. Takebayashi Y, Akiyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996; 78: 226-31.
20. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in pateints with node-negative colon cancer. Ann Surg 1995; 222: 695-9.
21. Margulles IMK, Hohtya M, Evans C, Loitta LA, Stetler-Stevenson WG. Urinary type IV collagenase: elevated levels associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomark Prevent 1992; 1: 467-74.
22. Nikkari ST, Hohtya M, Isola J, Nikkari T. Macrophages contain 92-kDa gelatinase (MMP-9) at the site of degenerated internal elastic lamina in temporal arteritis. Am J Pathol 1996; 149: 1427-33.
23. Cattorreti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357-63.
24. Morson BC, Sobin LH. Histological typing of intestinal tumors. International classification of tumors. No. 15. World Health Organization: Geneva
25. Astler VB, Coller FA, Michigan AA. The prognostic significance of direct extension of carcinoma of the colon and rectum 1958; 139: 846-52.
26. Stetler-Stevenson WG, Liotta LA, Keiner DE Jr. Extracellular matrix 6: role of matrix metalloproteianses in tumor invasion and metastasis. FASEB J 1993; 7: 1434-41.
27. Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y, Seiki M. Activation of the precursor of gelatinase A/ 72 kDa type IV collagenase/ MMP-2 in lung carcinomas correlates with the expression of membrane type matrix metalloproteianse (MT-MMP) and with lymph node metastasis. Int J Cancer 1995; 64: 355-9.
28. Ring P, Johansson K, Hohtya M, Rubin K, Lindmark G. Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer - a predictor of tumor stage. Br J Cancer 1997; 76: 805-11.
29. Emmert-Buck MR, Roth MJ, Zhuang Z, Campo E, Rozhin J, Sloane BF, Liotta LA, Stetler-Stevenson WG. Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 1994; 45: 1285-90.
30. Nagase J, Suzuki K, Morodomi T, Engfhlid JJ, Salvesen G. Activation mechanisms of the precursors of matrix metalloprotienases 1, 2, 3. Matrix 1992; Suppl 1: 237-44.
31. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995; 55: 2548-55.
32. Murphy G, Nguyen Q, Cockett MI, Williamson RAO, O'Shea M, Docherty A. The N-tenninal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 1991; 30: 8097-102.
33. Stongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanisms of cell surface activation of 72 kDa type IV collagenase. J Biol Chem 1995; 270: 1-8.
34. Powe DG, Brough JL, Carter GI, Bailey EM, Stetler-Stevenson WG, Turner DR, Hewitt RE. TIMP-3 mRNA expression is regionally increased in moderatedly and poorly differentiated colorectal adenocarcinoma. Br J Cancer 1997; 75: 1678-83.
35. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteianse-2 (TIMP-2) mRNA expresion in tumor cell lines and human tumor tissues. J Biol Chem 1990; 265: 13933-8.
36. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988; 48: 6863-71.
37. Bossi P, Viale G, Lee AKC, Alfano RM, Coggi G, Bosari S. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas & carcinomas with clinico-pathological correlations. Cancer Res 1995; 55: 5049-53.
38. Mlynek ML, van Beunigen D, Leder LD, Streffer C. Measurement of the grade of vascularisation in histological tumour tissue sections. Br J Cancer 1985; 52: 945-8.
39. Van de Rijn M, Rouse RV. CD34: a review. Appl Immunohistochem 1994; 2: 71-80.
40. Schlingemann RO, Rietveld FJR, De Waal RMW, Bradley N, Skene AI, Davies AJS, Greaves MS, Denekamp J, Ruiter DJ. Leukocyte angigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990; 62: 690-6.
41. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N, Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA 1997; 94: 861-6.
42. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636-49.
43. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
44. Fisher C, Gilbertson-Beadling S, Powers EA, Petzold G, Poorman R, Mitchell MA. Interstitial collagenase is required for angiogenesis in vitro. Devel Biol 1994; 162: 499-510.
45. Engel CJ, Bennett ST, Chambers AF, Doig GS, Kerkvilet N, O'Malley FP. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 1996; 20: 1260-5.